Announcements, portfolio news, and insights from IBC.
Stay current with leadership updates, funding milestones, and progress from the companies building the future of immune-mediated disease treatment.
Immune Boost Capital Invests in Orthrus Therapeutics to Advance Antigen-Specific Immune Tolerance for Autoimmune Disease
Immune Boost Capital (IBC), the venture investment arm of the Arthritis National Research Foundation (ANRF), today announced its investment in Orthrus Therapeutics, a company developing a new class of precision therapies for autoimmune disease with a strong focus on rheumatoid arthritis.
Where They're Headed Next: Celebrating Our First Summer Intern Cohort
This summer, four early-career scientists, engineers, and business minds joined Immune Boost Capital to support the research, diligence, and investment work behind our mission.
ANRF Announces Largest Scholar Cohort and Research Investment in Foundation History
As demand for independent research funding reaches an all-time high, the Arthritis National Research Foundation answers with its largest cohort, its biggest financial commitment, and a class of scientists tackling some of the most urgent questions in rheumatology today.
Immune Boost Capital Appoints Dr. Sai Nandi to Head Impact Investment Fund Targeting Immune-Mediated Diseases
Veteran biotech investor Dr. Sai Nandi joins IBC as Fund Principal to lead the expansion of the firm's venture fund and oversee its investment strategy in early-stage therapeutics, diagnostics, and enabling technologies for immune disorders.
More stories coming soon.
As we make new investments and share updates from our portfolio, you'll find those announcements here.